Description:
MRP1 is a 190kD transmembrane phosphoglycoprotein overexpressed in various human multidrug resistant tumor cell lines and tumors .
Applications:
Suitable for use in Immunocytochemistry, Flow Cytometry, Immunoprecipitation and Transport inhibition. Not recommended for use in Western Blot. Other applications have not been tested.
Recommended Dilutions:
Immunocytochemistry: use on paraformaldehyde (0.5% in PBS) fixed cytospin preparations
Flow Cytometry: 0.2-1ug/ml after fixing cells in 0.5% paraformaldehyde, followed by suitable fluorescent tagged anti-mouse reagent (6)
Transport Inhibition: Inhibits the ATP-dependent transport activity of MRP1 in inside-out membrane vessicles.
Optimal dilutions to be determined by the researcher.
Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
|
| Type | Isotype | Clone | Grade |
|---|
| Mab | IgG2a | 6D559 | Purified |
|
| Concentration: |
| ~0.04mg/ml |
| Immunogen: |
| Non-denatured membranes prepared from the human small cell lung cancer cell line H69AR, which highly overexpresses MRP1. |
| Purity: |
| Purified |
| Form |
| Supplied as a liquid in PBS, 0.7% BSA, 0.1% sodium azide. |
| Specificity: |
| Recognizes a conformation-dependent internal epitope (aa617-932) of human MRP1 overexpressed in various human non-P-glycoprotein MDR tumor cell lines. Does not cross-react with human P-glycoprotein, MDR3 P-glycoprotein, or mouse MRP gene products. |
|
| Intended for research use only. Not for use in human, therapeutic, or diagnostic applications. |
1. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies: D.R. Hipfner, et al.; Cancer Res. 54, 5788 (1994) 2. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell: K.C. Almquist, et al.; Cancer Res. 55, 102 (1995) 3. MRP and MDR1 gene expression in primary breast carcinomas: M. Filipits, et al.; Clin. Cancer Res. 2, 1231 (1996) 4. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport: D.W. Loe, et al.; J. Biol. Chem. 271, 9675 (1996) 5. MRP expression in acute myeloid leukemia. An update: M. Filipits, et al.; Adv. Exp. Med. Biol. 457, 141 (1999) 6. Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein: D.R. Hipfner, et al.; J. Biol. Chem. 274, 15420 (1999) 7. Structural, mechanistic and clinical aspects of MRP1: D.R. Hipfner, et al.; Biochim. Biophys. Acta 1461, 359 (1999) 8. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1: J. Renes, et al.; Br. J. Pharmacol. 126, 681 (1999)
|
|
